ENDRA Life Sciences regains Nasdaq minimum bid price compliance

ENDRA Life Sciences Inc.

Received Nasdaq confirmation on Nov 21, 2024 that it meets Listing Rule 5550(a)(2).
Avoids imminent delisting from Nasdaq; common stock (NDRA) continues trading.
Acting CEO Alex Tokman says company will now focus on new transformational strategies.

item 7.01 item 8.01 item 9.01

ENDRA Life Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001654954-24-014793

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.